Novartis Corporation Sustainability Profile
Novartis Corporation, a leading global healthcare company, is headquartered in the United States and operates extensively across Europe, Asia, and Latin America. Founded in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis has established itself as a key player in the pharmaceutical industry, focusing on innovative medicines, generics, and biosimilars. The company is renowned for its core products, including advanced therapies in oncology, cardiology, and immunology, which are distinguished by their cutting-edge research and development. Novartis has achieved significant milestones, such as the introduction of groundbreaking treatments that have transformed patient care. With a strong market position, Novartis continues to be recognised for its commitment to improving global health and advancing medical science.
DitchCarbon Score
How does Novartis Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novartis Corporation's score of 98 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
As of the latest available data, Novartis Corporation does not report specific carbon emissions figures, indicating a lack of detailed emissions data for the most recent year. The company is a current subsidiary of Novartis AG, which may influence its climate commitments and reporting practices. Novartis AG, the parent organisation, has established various climate initiatives and targets that cascade down to Novartis Corporation. These include commitments to the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all aimed at reducing carbon emissions and promoting sustainability. However, specific reduction targets or achievements for Novartis Corporation itself are not detailed in the available information. The absence of direct emissions data suggests that Novartis Corporation may still be in the process of developing or implementing its own specific climate strategies, while aligning with the broader goals set by Novartis AG. The company is expected to adhere to industry standards in climate terminology and practices as it works towards enhancing its environmental performance.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 583,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 922,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Novartis Corporation's Industry?
How Carbon Intensive is Novartis Corporation's Location?
Novartis Corporation's Scope 3 Categories Breakdown
Novartis Corporation's Scope 3 emissions, which decreased by 5% last year and increased significantly since 2013, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 78% of Scope 3 emissions.
Top Scope 3 Categories
Novartis Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Novartis Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
